Summary
In a placebo-controlled double-blind cross-over study, we gave 12 healthy male volunteers placebo or milnacipran orally, such that each volunteer received placebo and two doses of milnacipran. Blood samples taken before and at various times after dosing were analysed for plasma concentrations of unchanged milnacipran and the inhibitory effect of the plasma on the uptake of3H-5-hydroxytryptamine (5HT) into normal human platelets or of3H-noradrenaline into rat hypothalamus homogenate.
The mean maximal inhibition of 5HT and noradrenaline uptake was correlated with drug dose. The inhibition of 5HT uptake was correlated with the inhibition of noradrenaline uptake and both were correlated with plasma concentration of unchanged drug at all times and doses tested.
Thus, milnacipran, when given orally to man, circulates in a biologically active form with similar potency for the inhibition of 5HT and noradrenaline uptake.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonnaud B, Cousse H, Mouzin G, Briley M, Stenger A, Fauran F, Couzinier JP (1987) 1-aryl-2-(aminomethyl) cyclopropane-carboxylic acid derivatives. A new series of potential antidepressants. J Med Chem 30: 318–325
Bornstein S, Serre C, Quéméré A, Maloux H, Couzinier JP (1988) Determining the therapeutic dose of midalcipran (F 2207) in the treatment of dysthymia. Psychopharmacology 96: 273S
Braithwaite RA, Dawling S (1983) Prediction of steady-state plasma concentration and individual dosage requirements of tricyclic antidepressants from a single test dose. In: Burrows GD, Norman TR, Davies B (eds) Antidepressants. Drugs in psychiatry, vol. 1. Elsevier, Amsterdam, pp 97–109
Briley M (1986) Midalcipran. Drugs Future 11: 21–23
Demarez JP, Ansseau M, Serre C, Von Frenckell R, Sutet Ph (1988) A double-blind study comparing two doses of midalcipran (F 2207) to amitriptyline in major depressive disorders. Psychopharmacology 96: 273S
Lingjaerde O (1979) Inhibition of platelet uptake of 5-hydroxytryptamine in plasma from patients treated with clomipramine and amitriptyline. Eur J Pharmacol 15: 335–340
Moret C, Charveron M, Finberg JPM, Couzinier JP, Briley M (1985) Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl aminocarbonyl 2-aminomethyl cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant. Neuropharmacology 24: 1211–1219
Norman TR, Burrows GD (1983) Plasma concentrations of antidepressant drugs and clinical response. In: Burrows GD, Norman TR, Davies B (eds) Antidepressants. Drugs in psychiatry, vol. 1. Elsevier, Amsterdam, pp 111–120
Ogren SE, Ross S, Hall H, Archer T (1983) Biochemical and behavioural effects of antidepressant drugs. In: Burrows GD, Norman TR, Davies B (eds) Antidepressants. Drugs in psychiatry, vol. 1. Elsevier, Amsterdam, pp 13–34
Puozzo C, Rostin M, Montastruc JL, Houin G (1987) Absolute bioavailability of midalcipran (F 2207) in volunteers. In: Aiache JM, Hirtz J (eds). Third European Congress of Biopharmaceutics and Pharmacokinetics Proceedings, volume 1. Université de Clermont-Ferrand, pp 59–68
Serre C, Clerc G, Escande M, Feline A, Ginestet D, Tignol J, Van Amerogen P (1986) An early clinical trial of midalcipran, 1-phenyl-1-diethyl aminocarbonyl 2-aminomethyl cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant. Curr Ther Res 39: 156–164
Serre C, Elphick M, Grahame-Smith D, Moret C, Briley M (1988) Lack of anticholinergic action of midalcipran compared to amitriptyline in normal subjects. Psychopharmacology 96: 324S
Stenger A, Couzinier JP, Briley M (1987) Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-amino-methylcyclopropane hydrochloride (F 2207), a new potential antidepressant. Psychopharmacology 91: 147–153
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Palmier, C., Puozzo, C., Lenehan, T. et al. Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran. Eur J Clin Pharmacol 37, 235–238 (1989). https://doi.org/10.1007/BF00679776
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00679776